Recombinant IL5 (Mepolizumab Biosimilar) antibody
This Mammalian Cells Monoclonal antibody specifically detects IL5 (Mepolizumab Biosimilar) in ELISA. It exhibits reactivity toward Human.
Catalog No. ABIN7487818
$323.13
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant IL5 (Mepolizumab Biosimilar) antibody (ABIN7487818)
Target
IL5 (Mepolizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This IL5 (Mepolizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Mepolizumab Biosimilar - Anti-IL5 mAb
-
Characteristics
- Antibody Type: IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- IL5 (Mepolizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
SB-240563
Mepolizumab is a fully humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. (EGPA) and eosinophilia syndrome (HES). The pathogenesis of eosinophils is complex, but IL-5 is considered a key eosinophilic factor, involved in the differentiation, recruitment, activation and prolonged survival of eosinophils in peripheral tissues. Activated eosinophils further stimulate the inflammatory response, and also induce tissue damage and promote fibrosis, all of which contribute to the multifactorial symptoms of eosinophilic disease. Mepolizumab is used to treat severe asthma. -
CAS-No
- 196078-29-2
Target
-
You are here:
